Tech and Drugs – Podcast
Tech and Drugs - Podcast
Podcast Description
Welcome to Tech and Drugs, the podcast exploring how data and AI are revolutionizing Pharma and Biotech.
Each episode features candid conversations with industry experts tackling real-world challenges, sharing success stories, and lessons learned. Explore how digital transformation accelerates breakthroughs and bridges the gap between tech and science.
🔍 What You’ll Discover:
• How AI is driving drug discovery and development.
• Insights from the forefront of TechBio innovation.
• Practical lessons for navigating digital transformation.
Podcast Insights
Content Themes
The podcast explores themes centered on data and AI's transformative impact on Pharma and Biotech, with specific episodes covering topics like AI-driven drug discovery, practical steps for digital transformation, and the power of human-centric methodologies, highlighted in discussions around causes like the efficiency problem in pharma and the future of AI experimentation.

Welcome to Tech and Drugs, the podcast exploring how data and AI are revolutionizing Pharma and Biotech.
Each episode features candid conversations with industry experts tackling real-world challenges, sharing success stories, and lessons learned. Explore how digital transformation accelerates breakthroughs and bridges the gap between tech and science.
🔍 What You’ll Discover:
• How AI is driving drug discovery and development.
• Insights from the forefront of TechBio innovation.
• Practical lessons for navigating digital transformation.
Can AI run a laboratory—and if it can, what happens to the scientists?In this episode of Tech & Drugs, recorded at Lab of the Future, I sit down with Mike Tarselli, Chief Strategy Officer at Scitara, to explore the promises and practical challenges of autonomous science.Mike has worked across medicinal chemistry, pharmaceutical R&D, scientific data and AI. Together, we discuss what happens when AI agents move beyond analyzing data and begin interacting with instruments, designing workflows and helping drive experiments.But we also ask a less glamorous question: how do you build the lab of the future when some of the instruments you rely on were built decades ago?We cover:• Whether autonomous science still needs human scientists—and what their role might become.• Why scientific leaders need to think about aligning AI agents with scientific goals.• Anthropic’s Model Hardware Standard, lab connectivity and the challenge of bringing older instruments into an agentic world.• What it means for frontier AI companies to build their own laboratories—and how that could change their relationship with pharma.• Scientific data, intellectual property and the questions researchers should ask when using AI tools.• Why measuring progress in AI-enabled drug discovery is harder than it looks.• How we might measure the return on investment of AI in R&D.• Why Mike believes the lab may need a new kind of professional: the “robot farmer.”🎙️ Guest: Mike Tarselli, Chief Strategy Officer, Scitara 🎤 Host: Thibault Géoui 📍 Recorded at Lab of the FutureConnect with Scitara: https://scitara.com/Follow Tech & Drugs for more conversations at the intersection of science, technology and drug R&D.**Chapters**00:00 — Welcome from Lab of the Future 02:05 — Mike’s journey from medicinal chemistry to lab technology 07:45 — Does good science still need humans? 11:45 — Scientific alignment and the role of scientific leaders 15:15 — Anthropic’s Model Hardware Standard and AI-connected instruments 17:45 — The legacy instrument problem: no instrument left behind 20:00 — When frontier AI companies build their own labs 23:00 — Virtual research teams, pharma partnerships and culture 29:25 — AI, scientific ideas and data protection 33:00 — Where are the AI-developed drugs? 38:00 — Measuring AI’s return on investment 40:15 — The future of the lab and the rise of the “robot farmer” 42:10 — Closing thoughtsWhat do you think: will the scientist of the future spend more time at the bench—or orchestrating a fleet of AI agents and instruments?

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.